Stahl's Essential Psychopharmacology Online
In Collaboration With
Index
The 
-icon indicates content; the 
-icon indicates figures; the 
-icon indicates tables.
- G protein, binding to receptor-neurotransmitter complex,
- G protein-linked receptors, , ,
- chemical neurotransmission,
- psychotropic drug action on,
- as psychotropic drug indirect target,
- as psychotropic drug target, ,
- with agonists, ,
- with antagonists
- inverse agonists,
- light and dark as analogy for partial agonists,
- with no agonist,
- with partial agonists, ,
- structure and function, ,
- superfamily,
- G protein-linked signal-transduction cascades, ,
- binary neurotransmitter receptor complex binding to G protein,
- elements of,
- first messengers, ,
- functional outcome of neurotransmission,
- later messengers,
- second messenger, ,
- key elements,
- release,
- GABA (gamma-aminobutyric acid), , ,
- alcohol actions at synapses,
- anxiety and, ,
- and anxiety disorders, ,
- and anxiety regulation in amygdala,
- anxiolytics,
- binding sites,
- estrogen and,
- production, ,
- as psychotropic drug indirect target,
- as psychotropic drug target, , ,
- psychotropic drugs and,
- sleep/wake switch regulation, ,
- in thalamus, and insomnia,
- topiramate and,
- transporters,
- valproate and,
- GABA-A allosteric modulatory sites, hypothetical shift in set point,
- GABA-A PAMs, and psychiatric insomnia,
- GABA agonist site,
- GABA-ergic agents, potential therapeutic effects,
- GABA (gamma-aminobutyric acid),
- possible valproate sites of action,
- GABA (gamma-aminobutyric acid) A receptors, pentameric structure,
- GABA (gamma-aminobutyric acid) inhibitor, estrogen as,
- GABA (gamma-aminobutyric acid) interneurons, estrogen and,
- GABA (gamma-aminobutyric acid) neurons, ,
- for connecting serotonin and dopamine neurons,
- dopamine impact on,
- release,
- and sleepiness circuits,
- GABA neurotransmitter,
- GABA receptors
- GABA-A subtypes, ,
- mediation of tonic and phasic inhibition,
- positive allosteric modulation,
- subtypes, ,
- GABA reuptake pump,
- GABA transaminase (GABA-T), ,
- GABA transporter (GAT),
- GABA vesicular transporter,
- GABAergic inhibitory interneurons, ,
- gabapentin, ,
- for anxiety disorders,
- binding to alpha-2 delta protein,
- channel blocking by,
- in combos for bipolar disorder,
- for fibromyalgia,
- icon,
- mechanism of action
- on GABA, glutamate, sigma, and dopamine,
- VSSCs, synaptic vesicles, and carbonic anhydrase,
- for panic disorder,
- putative clinical actions,
- for social anxiety disorder,
- gaboxadol,
- GAD (glutamic acid decarboxylase), ,
- galactorrhea, ,
- galantamine,
- actions,
- icon,
- Gamanil. See Llofrepramine (Deprimyl, Gamanil)
- gambling,
- compulsive,
- gamma-aminobutyric acid (GABA). See GABA (gamma-aminobutyric acid)
- gamma hydroxybutyrate (GHB),
- for fibromyalgia,
- for wakefulness,
- gamma secretase,
- inhibitors and modulators, ,
- gamma units, ,
- gases, as neurotransmitters,
- gastrointestinal cramps, for serotonin receptor stimulation,
- gastrointestinal upset, from paroxetine withdrawal,
- GAT, transporters for,
- “gate theory” of pain,
- GC (guanylyl cyclase), ,
- GDNF (glial cell line–derived neurotrophic factors), ,
- gene expression
- enzymes regulating,
- messenger triggering of,
- neurotransmission regulation of,
- signal-transduction cascades influence, ,
- generalized anxiety disorder (GAD),
- insomnia with,
- pharmacy,
- symptoms shared with other disorders,
- treatment,
- genes
- 5HT2A antagonists and expression,
- activation
- early, impact on late,
- factors affecting,
- with gene turned on,
- late, ,
- products,
- when gene is off,
- encoding of proteins, ,
- hypothetic regulation of mood networks,
- hypothetical path to behavior,
- hypothetical path to mental illness,
- immediate-early, ,
- monoamine hypothesis of antidepressant action on expression,
- in mood disorders, ,
- quantitative methods measuring abnormal,
- regulation by neurotransmitters,
- as signal-transduction target, , ,
- susceptibility,
- for schizophrenia,
- genetic abnormalities, degrees, and environmental stressors, ,
- genetic G protein-linked receptors,
- genetic programming, in neurodegenerative theories of schizophrenia,
- genetics in psychiatry,
- classic theory, ,
- imaging, ,
- new paradigm,
- and prefrontal cortex abnormalities in ADHD,
- genomes,
- apoptosis programmed into,
- decoding of incoming signals,
- neurotransmitter signaling between, ,
- protein orders from,
- gepirone, ,
- and anxiety disorders,
- GHB (gamma hydroxybutyrate), for fibromyalgia,
- ginko biloba, for Alzheimer’s disease,
- glial alanine-serine-cysteine transporter (ASC-T),
- glial cell line–derived neurotrophic factor (GDNF), ,
- glial cells,
- glutamine release from,
- glycine from,
- and neuronal migration,
- glial d-serine transporter,
- glial derived neurotrophic factor,
- glial SNAT, ,
- glucocorticoid antagonists, ,
- potential for clinical use,
- glucocorticoid receptors,
- glucocorticoids, release as stress response, ,
- glucose
- monitoring fasting,
- PET scan to measure uptake,
- glutamate, ,
- 5HT2A antagonists and inhibitory action of HT1A on release,
- agonist actions at 5HT1A receptors and,
- at AMPA and kainite receptors,
- antipsychotic agents and,
- binding to NMDA complex,
- calcium channels associated with,
- conversion to glutamine, , ,
- as cortical pyramidal neuron output,
- estrogen as activator,
- excitotoxicity
- amyloid plaques and,
- system overactivity, ,
- GABA synthesis from,
- key pathways in brain, ,
- NMDA hypofunction hypothesis of schizophrenia and, ,
- mood stabilizers action on,
- NMDA receptor excitation spectrum by,
- for open calcium channel,
- pharmacology,
- preventing release,
- psychotropic drugs and, , ,
- recycled and regnerated,
- conversion to glutamine,
- glutamine release from glial cells,
- reducing hyperactivity, with atypical antipsychotics,
- release
- 5HT1A and 5HT2A receptor effect,
- amyloid plaques and,
- of excessive,
- lamotrigine impact on,
- from presynaptic neuron,
- presynaptic nicotinic heteroreceptors and,
- regulation with 5HT1A, ,
- riluzole to prevent
- serotonin inhibition of,
- serotonin stimulation of,
- role in schizophrenia pathophysiology,
- signal transduction of,
- susceptibility gene effect on,
- synapses, convergence of susceptibility genes for schizophrenia on,
- synthesis,
- topiramate and,
- glutamate receptors, ,
- metabotropic, ,
- signal propagation,
- types,
- glutamate transporters, , ,
- structure,
- as trimers,
- glutamatergic corticostriatal projections, NMDA glutamate receptor hypofunction in,
- glutamatergic excitatory projections, from thalamus,
- glutamic acid decarboxylase (GAD), ,
- glutaminase, ,
- glutamine
- glutamate conversion to, , ,
- release from glial cells,
- glutamine synthetase,
- glycine, , ,
- binding to NMDA complex,
- from glial cells,
- from l-serine,
- production,
- glycine agonists,
- glycine receptors,
- pentameric structure,
- glycine transporters (GlyT1), , ,
- inhibitors,
- glycogen synthetase kinase 3 (GSK3), , ,
- glycogen synthetase kinase (GSK)
- inhibitors for Alzheimer’s disease,
- lithium and,
- goal-directed activity
- circuit,
- turning reward into, ,
- “God’s pharmacopeia”,
- “Goldilocks” solution, ,
- Golgi apparatus, ,
- localization of,
- protein modification, ,
- grandiose expansiveness,
- grandiosity,
- in hyperthymic temperament,
- inefficient information processing and,
- growth cone, axonal, ,
- docking,
- growth factor
- in brain,
- fast transport of,
- restoration of neurons by,
- transport to soma, ,
- GSI 953,
- GSK. See glycogen synthetase kinase (GSK)
- GSK-3 (glycogen synthase kinase 3), , ,
- guanfacine, for ADHD, ,
- guanosine monophosphate (cGMP), ,
- guanylyl cyclase (GC), ,
- guilt,
- circuits,
- serotonin and,
- gut,
- CYP450 enzymes in wall,
- gut hormones,
- GW742457,